dm+d

327370004

Articles

Safety in Lactation: Drugs affecting gonadotrophins

17 September 2020The most common use of these drugs in women is for endometriosis, the symptoms of which may be supressed during pregnancy and while breastfeeding. The…
Search Articles

Refrigerated Storage

Gonapeptyl DepotFerring Pharmaceuticals Ltd

Ferring Pharmaceuticals Ltd
Gonapeptyl Depot
3.75 mg powder and solvent for suspension for injection

Contact Ferring (UK) in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk.

Keep in the outer carton to protect from light.

27 December 2019
London MI Service

Lactation Safety Information

Buserelin
No published evidence of safety
Negligible levels anticipated in milk, due to drug’s properties, with subsequent minimal absorption from the infant’s GI tract
16 September 2020

New Medicines

DecapeptylProstate cancer - 11.25mg subcutaneous formulation

Information

Decapeptyl
New formulation
Ipsen
Debiopharm

Development and Regulatory status

Filing withdrawn
Filing withdrawn
None
Apr 19Ipsen withdraws a MAA to the EMA for Decapeptyl 3M subcutaneous administration. Due to the overwhelming uncertainty in the current political environment and the unknown impact on supply and distribution of medicine, Ipsen does not feel it is an appropriate time to launch a new route of administration. Ipsen will continue to monitor the political environment and reassess the application when it feels appropriate for the UK market [5].

Category

Synthetic decapeptide analogue of natural gonadotropin-releasing hormone analogue. Given 3-monthly.
The age-standardised incidence of prostate cancer in the UK in 2014 was 175 per 100,000 population
Prostate cancer - 11.25mg subcutaneous formulation
Subcutaneous injection

Evidence based evaluations